Business Description
Pacira BioSciences Inc
NAICS : 325412
SIC : 2834
ISIN : US6951271005
Total Employee Number:
829Compare
Compare
Traded in other countries / regions
PCRX.USA82P.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2011-02-03Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.63 | |||||
Debt-to-EBITDA | 3.47 | |||||
Interest Coverage | 1.14 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 1.94 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4 | |||||
3-Year EBITDA Growth Rate | -3.4 | |||||
3-Year EPS without NRI Growth Rate | 0.8 | |||||
3-Year FCF Growth Rate | 7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.54 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.28 | |||||
9-Day RSI | 71.5 | |||||
14-Day RSI | 66.12 | |||||
3-1 Month Momentum % | -1.98 | |||||
6-1 Month Momentum % | -9.04 | |||||
12-1 Month Momentum % | -4.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.73 | |||||
Quick Ratio | 3.35 | |||||
Cash Ratio | 1.86 | |||||
Days Inventory | 357.09 | |||||
Days Sales Outstanding | 58.02 | |||||
Days Payable | 48.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.6 | |||||
Shareholder Yield % | 36.92 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.34 | |||||
Operating Margin % | 2.18 | |||||
Net Margin % | 0.7 | |||||
EBITDA Margin % | 16.11 | |||||
FCF Margin % | 18.06 | |||||
OCF Margin % | 19.35 | |||||
ROE % | 0.71 | |||||
ROA % | 0.37 | |||||
ROIC % | 0.64 | |||||
3-Year ROIIC % | 14.44 | |||||
ROC (Joel Greenblatt) % | 6.95 | |||||
ROCE % | 2.29 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 211.67 | |||||
Forward PE Ratio | 8.83 | |||||
PE Ratio without NRI | 11.72 | |||||
Shiller PE Ratio | 187.98 | |||||
Price-to-Owner-Earnings | 32.19 | |||||
PS Ratio | 1.5 | |||||
PB Ratio | 1.53 | |||||
Price-to-Tangible-Book | 3.55 | |||||
Price-to-Free-Cash-Flow | 8.31 | |||||
Price-to-Operating-Cash-Flow | 7.75 | |||||
EV-to-EBIT | 44.4 | |||||
EV-to-Forward-EBIT | 26.57 | |||||
EV-to-EBITDA | 10.21 | |||||
EV-to-Forward-EBITDA | 9.37 | |||||
EV-to-Revenue | 1.64 | |||||
EV-to-Forward-Revenue | 1.57 | |||||
EV-to-FCF | 9.11 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Projected-FCF | 0.58 | |||||
Price-to-Median-PS-Value | 0.32 | |||||
Price-to-Graham-Number | 1.36 | |||||
Earnings Yield (Greenblatt) % | 2.25 | |||||
FCF Yield % | 13.28 | |||||
Forward Rate of Return (Yacktman) % | -0.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PCRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pacira BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 734.864 | ||
| EPS (TTM) ($) | 0.12 | ||
| Beta | 0.1578 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.25 | ||
| Volatility % | 48.14 | ||
| 14-Day RSI | 66.12 | ||
| 14-Day ATR ($) | 0.957493 | ||
| 20-Day SMA ($) | 23.623 | ||
| 12-1 Month Momentum % | -4.14 | ||
| 52-Week Range ($) | 18.8 - 27.64 | ||
| Shares Outstanding (Mil) | 39.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pacira BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pacira BioSciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 123 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 30 days | ||
| General meeting for 2026 | 2026-06-09 | 22.86 (+0.70%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 13:20 | 22.75 (-0.74%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 22.25 (-3.09%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 08:30 | 22.31 (-1.02%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 16:30 | 25.14 (-0.44%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 25.14 (-0.44%) |
Show
Entries
Pacira BioSciences Inc Frequently Asked Questions
What is Pacira BioSciences Inc(PCRX)'s stock price today?
The current price of PCRX is $25.40. The 52 week high of PCRX is $27.64 and 52 week low is $18.80.
When is next earnings date of Pacira BioSciences Inc(PCRX)?
The next earnings date of Pacira BioSciences Inc(PCRX) is 2026-08-05 Est..
Does Pacira BioSciences Inc(PCRX) pay dividends? If so, how much?
Pacira BioSciences Inc(PCRX) does not pay dividend.
Guru Commentaries on NAS:PCRX
No articles.
Press Release
Articles on Pacira BioSciences Inc
No articles.
Headlines
See More- 1
Jun 30, 2026
Pacira divesting iovera° unit to Zimmer Biomet
Seeking Alpha • 7:47am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers